43029-72-7

Basic information

• Product Name: 4-HYDROXY-4'-TRIFLUOROMETHYL-BIPHENYL-3-CARBOXYLIC ACID
• Synonyms: AKOS BAR-0039;4-HYDROXY-4'-(TRIFLUOROMETHYL)[1,1'-BIPHENYL]- 3-CARBOXYLIC ACID;4-HYDROXY-4'-TRIFLUOROMETHYL-BIPHENYL-3-CARBOXYLIC ACID
• CAS NO: 43029-72-7
• Molecular Formula: C₁₄H₉F₃O₃
• Molecular Weight: 282.21
• Mol File: 43029-72-7.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-HYDROXY-4'-TRIFLUOROMETHYL-BIPHENYL-3-CARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 4-HYDROXY-4'-TRIFLUOROMETHYL-BIPHENYL-3-CARBOXYLIC ACID(43029-72-7)
• EPA Substance Registry System: 4-HYDROXY-4'-TRIFLUOROMETHYL-BIPHENYL-3-CARBOXYLIC ACID(43029-72-7)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 43029-72-7(Hazardous Substances Data)

Upstream product

• 696-62-8 para-iodoanisole 
• 89-55-4 5-bromosalicyclic acid 
• 128796-39-4 4-trifluoromethylphenylboronic acid 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 439146-17-5 C₁₅H₁₁F₃O₃ 
• 455-13-0 4-Iodobenzotrifluoride 
• 124-38-9 carbon dioxide 
• 10355-12-1 1-(4-methoxyphenyl)-4-(trifluoromethyl)benzene 

Relevant articles and documents

NF-KB ACTIVATION INHIBITORS

A medicament having inhibitory activity against NF-κB activation which comprises as an active ingredient a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof: wherein A represents hydrogen atom or acetyl group, E represents a 2,5-di-substituted or a 3,5-di-substituted phenyl group, or a monocyclic or a fused polycyclic heteroaryl group which may be substituted, provided that the compound wherein said heteroaryl group is 1○ a fused polycyclic heteroaryl group wherein the ring which binds directly to ―CONH― group in the formula (I) is a benzene ring, 2○ unsubstituted thiazol-2-yl group, or 3○ unsubstituted benzothiazol-2-yl group is excluded, ring Z represents an arene which may have one or more substituents in addition to the group represented by formula ―O―A wherein A has the same meaning as that defined above and the group represented by formula -CONH-E wherein E has the same meaning as that defined above, or a heteroarene which may have one or more substituents in addition to the group represented by formula ―O―A wherein A has the same meaning as that defined above and the group represented by formula ― CONH―E wherein E has the same meaning as that defined above.

REMEDIES FOR NEURODEGENERATIVE DISEASES

A medicament for preventive and/or therapeutic treatment of neurodegenerative diseases such as Alzheimer's disease or the like which comprises as an active ingredient a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof: wherein A represents hydrogen atom or acetyl group, E represents a 2,5-di-substituted or a 3,5-di-substituted phenyl group, or a monocyclic or a fused polycyclic heteroaryl group which may be substituted, provided that the compound wherein said heteroaryl group is 1○ a fused polycyclic heteroaryl group wherein the ring which binds directly to -CONH- group in the formula (I) is a benzene ring, 2○ unsubstituted thiazol-2-yl group, or 3○ unsubstituted benzothiazol-2-yl group is excluded, ring Z represents an arene which may have one or more substituents in addition to the group represented by formula -O-A wherein A has the same meaning as that defined above and the group represented by formula -CONH-E wherein E has the same meaning as that defined above, or a heteroarene which may have one or more substituents in addition to the group represented by formula -O-A wherein A has the same meaning as that defined above and the group represented by formula -CONH-E wherein E has the same meaning as that defined above.

ANTIALLERGIC

A medicament for the preventive and/or therapeutic treatment of allergic diseases and/or endometriosis and/or hysteromyoma which comprises as an active ingredient a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof: wherein X represents a connecting group whose number of atoms in the main chain is 2 to 5 (said connecting group may be substituted), A represents hydrogen atom or acetyl group, E represents an aryl group which may be substituted or a hetero aryl group which may be substituted, ring Z represents an arene which may have one or more substituents in addition to the group represented by formula -O-A wherein A has the same meaning as that defined above and the group represented by formula -X-E wherein each of X and E has the same meaning as that defined above, or a heteroarene which may have one or more substituents in addition to the group represented by formula -O-A wherein A has the same meaning as that defined above and the group represented by formula -X-E wherein each ofX and E has the same meaning as that defined above.